Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

This metabolic condition directly affects the bones by reducing its density as well as quality. "In the individuals suffering ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases ...

In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...

Healthy diet and regular exercise are key to treating obesity. But the stress of everyday racism and sexism hinder Black ...

Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes ...

Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday after a ...